MENLO PARK, Calif., Oct. 21, 2015 (GLOBE NEWSWIRE) -- Exponent, Inc. (Nasdaq:EXPO) today reported financial results for the third quarter and nine months ended October 2, 2015.

For the third quarter of 2015, revenues before reimbursements increased to $74,503,000 from $74,264,000 in the third quarter of 2014. Total revenues increased to $78,994,000 from $78,557,000 in the same period one year ago.

Net income for the third quarter increased 6% to $11,719,000 from $11,040,000 in the third quarter of 2014. Earnings per diluted share increased to $0.43 as compared to $0.40 in the same quarter last year. EBITDA1 increased 2% to $20,055,000 as compared to $19,688,000 in the same period one year ago.

For the first nine months of 2015, revenues before reimbursements increased 3% to $225,916,000 from $219,562,000 in the first nine months of 2014. Total revenues increased 3% to $239,151,000 from $231,093,000 in the same period one year ago.

Net income for the first nine months of 2015 increased 7% to $33,749,000 from $31,458,000 in the first nine months of 2014. Earnings per diluted share increased to $1.23, as compared to $1.13 in the same period of last year. EBITDA1 increased 5% to $59,055,000 as compared to $56,000,000 in the same period one year ago.

Year to date 2015, Exponent generated $34.3 million in cash from operating activities, repurchased $19.8 million of common stock and paid dividends of $11.8 million. The Company closed the quarter with $151.3 million in cash, cash equivalents and short-term investments.

In a separate release today, Exponent announced that its Board of Directors has authorized an additional $35 million in share repurchases, increasing the Company's current authorization to approximately $50 million. Exponent also announced its quarterly cash dividend of $0.15 to be distributed on December 18, 2015 and its intent to continue to pay quarterly dividends.

"We are pleased to have continued our solid growth of the bottom line in the third quarter, especially considering the impact of a major project wrapping up and a decline in defense technology development, which we previously articulated," commented Dr. Paul Johnston, President and CEO. "During the third quarter, we experienced good demand in both our proactive and reactive services and saw notable performance from our materials, polymer science, biomedical, and vehicle engineering practices, as well as our infrastructure group."

"Year to date, our underlying growth has been in the high single digits but has been offset by a significant decline in defense work and the end of a major project. Based on our year to date results, we are reiterating our expectations for the growth of revenues before reimbursements to be in the low single digits for fiscal year 2015. We expect EBITDA1 margin to be essentially flat with the 25% we achieved in 2014, a slight improvement to our prior outlook."

"Exponent continues to be called upon to investigate the most significant accidents and to support critical programs for companies globally. We are optimistic about our ability to leverage our strong market position for reactive service to grow our client relationships into design consulting, risk management and regulatory support," concluded Dr. Johnston.

Today's Conference Call Information

Exponent will discuss its financial results in more detail on a conference call today, Wednesday, October 21, 2015, starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. The audio of the conference call is available by dialing (888) 427-9411 or (719) 325-2484. A live webcast of the call will be available on the Investor Relations section of the Company's website at www.exponent.com/investors. For those unable to listen to the live webcast, a replay of the call will also be available on the Exponent website, or by dialing (888) 203-1112 or (719) 457-0820, and entering passcode 586851#.

About Exponent

Exponent is an engineering and scientific consulting firm providing solutions to complex problems. Exponent's multidisciplinary organization of scientists, physicians, engineers, and business consultants brings together more than 90 technical disciplines to address complicated issues facing industry and government today. The firm has been best known for analyzing accidents and failures to determine their causes, but in recent years it has become more active in assisting clients with human health, environmental and engineering issues associated with new products to help prevent problems in the future.

Exponent may be reached at (888) 656-EXPO, info@exponent.com, or www.exponent.com.

This news release contains, and incorporates by reference, certain "forward-looking" statements (as such term is defined in the Private Securities Litigation Reform Act of 1995, and the rules promulgated pursuant to the Securities Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended thereto under) that are based on the beliefs of the Company's management, as well as assumptions made by and information currently available to the Company's management. The Private Securities Litigation Reform Act of 1995 subject to the safe harbor creates such forward-looking statements. When used in this document and in the documents incorporated herein by reference, the words "anticipate," "believe," "estimate," "expect" and similar expressions, as they relate to the Company or its management, identify such forward-looking statements. Such statements reflect the current views of the Company or its management with respect to future events and are subject to certain risks, uncertainties and assumptions. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, the Company's actual results, performance, or achievements could differ materially from those expressed in, or implied by, any such forward-looking statements. Factors that could cause or contribute to such material differences include the possibility that the demand for our services may decline as a result of changes in general and industry specific economic conditions, the timing of engagements for our services, the effects of competitive services and pricing, the absence of backlog related to our business, our ability to attract and retain key employees, the effect of tort reform and government regulation on our business, and liabilities resulting from claims made against us. Additional risks and uncertainties are discussed in our Annual Report on Form 10K under the heading "Risk Factors" and elsewhere in the report. The inclusion of such forward-looking information should not be regarded as a representation by the Company or any other person that the future events, plans, or expectations contemplated by the Company will be achieved. The Company undertakes no obligation to release publicly any updates or revisions to any such forward-looking statements.

1 EBITDA is a non-GAAP financial measure defined by the Company as net income before income taxes, interest income, depreciation and amortization. EBITDAS is a non-GAAP financial measure defined by the Company as EBITDA before stock-based compensation. The Company regards EBITDA and EBITDAS as useful measures of operating performance and cash flow to complement operating income, net income and other GAAP financial performance measures. Additionally, management believes that EBITDA and EBITDAS provide meaningful comparisons of past, present and future operating results. Generally, a non-GAAP financial measure is a numerical measure of a company's performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. These measures, however, should be considered in addition to, and not as a substitute or superior to, operating income, cash flows, or other measures of financial performance prepared in accordance with GAAP. A reconciliation of the measures to GAAP is set forth below.

EXPONENT, INC.
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
For the Quarters Ended October 2, 2015 and October 3, 2014
(unaudited)
(in thousands, except per share data)
         
     
  Quarter Ended  Nine Months Ended 
  October 2,  October 3,  October 2,  October 3, 
  2015  2014  2015  2014 
         
Revenues        
Revenues before reimbursements  $ 74,503  $ 74,264  $ 225,916  $ 219,562
Reimbursements  4,491  4,293  13,235  11,531
         
Revenues  78,994  78,557  239,151  231,093
         
Operating expenses        
Compensation and related expenses  42,853  43,948  139,745  138,855
Other operating expenses  6,766  6,715  19,979  19,482
Reimbursable expenses  4,491  4,293  13,235  11,531
General and administrative expenses  3,963  4,363  11,538  11,809
         
   58,073  59,319  184,497  181,677
         
Operating income  20,921  19,238  54,654  49,416
         
Other income (expense), net        
Interest income, net  47  33  115  117
Miscellaneous income, net  (2,195)  (896)  367  2,605
   (2,148)  (863)  482  2,722
         
Income before income taxes  18,773  18,375  55,136  52,138
         
Income taxes  7,054  7,335  21,387  20,680
         
         
Net income  $ 11,719  $ 11,040  $ 33,749  $ 31,458
         
         
Net income per share:        
Basic  $ 0.44  $ 0.41  $ 1.27  $ 1.16
Diluted  $ 0.43  $ 0.40  $ 1.23  $ 1.13
         
Shares used in per share computations:        
Basic  26,597  26,938  26,644  27,018
Diluted  27,268  27,648  27,350  27,778
 
EXPONENT, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
October 2, 2015 and January 2, 2015
(unaudited)
(in thousands)
     
     
  October 2,  January 2, 
  2015  2015 
Assets    
Current assets:    
Cash and cash equivalents  $ 124,457  $ 129,490
Short-term investments  26,837  24,913
Accounts receivable, net  94,168  86,368
Prepaid expenses and other assets  12,884  14,727
Deferred income taxes  11,112  11,002
Total current assets  269,458  266,500
Property, equipment and leasehold improvements, net  29,390  28,264
Goodwill  8,607  8,607
Other assets  61,526  61,928
   $ 368,981  $ 365,299
     
Liabilities and Stockholders' Equity    
Current liabilities:    
Accounts payable and accrued liabilities  $ 8,945  $ 8,935
Accrued payroll and employee benefits  54,726  62,184
Deferred revenues  5,892  8,226
Total current liabilities  69,563  79,345
Other liabilities  40,650  39,607
Deferred rent  1,979  2,059
Total liabilities  112,192  121,011
     
Stockholders' equity:    
Common stock  33  33
Additional paid-in capital  177,129  160,208
Accumulated other comprehensive (loss)/income  (1,443)  (904)
Retained earnings  263,417  246,961
Treasury stock, at cost  (182,347)  (162,010)
Total stockholders' equity  256,789  244,288
   $ 368,981  $ 365,299
 
EXPONENT, INC. 
EBITDA and EBITDAS (1) 
For the Quarters Ended October 2, 2015 and October 3, 2014
(unaudited)
(in thousands)
         
     
  Quarter Ended  Nine Months Ended 
  October 2,  October 3,  October 2,  October 3, 
  2015  2014  2015  2014 
         
Net Income  $ 11,719  $ 11,040  $ 33,749  $ 31,458
         
Add back (subtract):        
         
Income taxes  7,054  7,335  21,387  20,680
Interest income, net  (47)  (33)  (115)  (117)
Depreciation and amortization  1,329  1,346  4,034  3,979
         
EBITDA (1)  20,055  19,688  59,055  56,000
         
Stock-based compensation  2,634  2,710  10,536  10,585
         
EBITDAS (1)  $ 22,689  $ 22,398  $ 69,591  $ 66,585
         
         
         
(1) EBITDA is a non-GAAP financial measure defined by the Company as net income before income taxes, interest income, depreciation and amortization. EBITDAS is a non-GAAP financial measure defined by the Company as EBITDA before stock-based compensation. The Company regards EBITDA and EBITDAS as useful measures of operating performance and cash flow to compliment operating income, net income and other GAAP financial performance measures. Additionally, management believes that EBITDA and EBITDAS provide meaningful comparisons of past, present and future operating results. Generally, a non-GAAP financial measure is a numerical measure of a company's performance, financial position or cash flow that either excludes or includes amounts that are not normally excluded or included in the most directly comparable measure calculated and presented in accordance with GAAP. These measures, however, should be considered in addition to, and not as a substitute or superior to, operating income, cash flows, or other measures of financial performance prepared in accordance with GAAP.